MA38193B1 - Utilisation d'inhibiteurs de télomérase pour le traitement de troubles myéloprolifératifs et de néoplasies myéloprolifératives - Google Patents
Utilisation d'inhibiteurs de télomérase pour le traitement de troubles myéloprolifératifs et de néoplasies myéloproliférativesInfo
- Publication number
- MA38193B1 MA38193B1 MA38193A MA38193A MA38193B1 MA 38193 B1 MA38193 B1 MA 38193B1 MA 38193 A MA38193 A MA 38193A MA 38193 A MA38193 A MA 38193A MA 38193 B1 MA38193 B1 MA 38193B1
- Authority
- MA
- Morocco
- Prior art keywords
- myeloproliferative
- telomerase inhibitors
- treatment
- myeloproliferative disorders
- disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Otolaryngology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Compounds Of Unknown Constitution (AREA)
Abstract
La présente invention concerne des procédés pour réduire la prolifération de cellules progénitrices néoplasiques et soulager des symptômes associés chez des individus diagnostiqués avec ou suspectés d'avoir des troubles myéloprolifératifs, tels que la thrombocytémie essentielle (te). La présente invention concerne en outre des procédés d'utilisation d'inhibiteurs de télomérase pour maintenir les numérations plaquettaires sanguines dans des plages relativement normales dans le sang d'individus diagnostiqués avec ou suspectés d'avoir des troubles myéloprolifératifs, tels que te.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261734941P | 2012-12-07 | 2012-12-07 | |
US201361799069P | 2013-03-15 | 2013-03-15 | |
US13/841,711 US9375485B2 (en) | 2012-12-07 | 2013-03-15 | Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms |
US201361900347P | 2013-11-05 | 2013-11-05 | |
PCT/US2013/070437 WO2014088785A1 (fr) | 2012-12-07 | 2013-11-15 | Utilisation d'inhibiteurs de télomérase pour le traitement de troubles myéloprolifératifs et de néoplasies myéloprolifératives |
Publications (2)
Publication Number | Publication Date |
---|---|
MA38193A1 MA38193A1 (fr) | 2017-12-29 |
MA38193B1 true MA38193B1 (fr) | 2018-12-31 |
Family
ID=50883867
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA45504A MA45504B1 (fr) | 2012-12-07 | 2013-11-15 | Utilisation d'inhibiteurs de télomérase pour le traitement de troubles myéloprolifératifs et de néoplasies myéloprolifératives |
MA38193A MA38193B1 (fr) | 2012-12-07 | 2013-11-15 | Utilisation d'inhibiteurs de télomérase pour le traitement de troubles myéloprolifératifs et de néoplasies myéloprolifératives |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA45504A MA45504B1 (fr) | 2012-12-07 | 2013-11-15 | Utilisation d'inhibiteurs de télomérase pour le traitement de troubles myéloprolifératifs et de néoplasies myéloprolifératives |
Country Status (34)
Country | Link |
---|---|
EP (3) | EP3456333B8 (fr) |
JP (5) | JP6433911B2 (fr) |
KR (3) | KR102662590B1 (fr) |
CN (2) | CN104936602B (fr) |
AP (1) | AP2015008504A0 (fr) |
AU (3) | AU2013356533B2 (fr) |
BR (1) | BR112015013260A2 (fr) |
CA (2) | CA2892907C (fr) |
CL (2) | CL2015001530A1 (fr) |
CY (2) | CY1122169T1 (fr) |
DK (3) | DK3646876T3 (fr) |
EA (1) | EA032973B1 (fr) |
ES (2) | ES2789176T3 (fr) |
FI (1) | FI3646876T3 (fr) |
HK (2) | HK1210940A1 (fr) |
HR (2) | HRP20191784T1 (fr) |
HU (2) | HUE045098T2 (fr) |
IL (2) | IL239266B (fr) |
LT (3) | LT3456333T (fr) |
MA (2) | MA45504B1 (fr) |
ME (1) | ME03538B (fr) |
MX (3) | MX2015007169A (fr) |
MY (1) | MY180634A (fr) |
NZ (1) | NZ708920A (fr) |
PH (1) | PH12015501282A1 (fr) |
PL (2) | PL2928477T3 (fr) |
PT (2) | PT3456333T (fr) |
RS (2) | RS60401B1 (fr) |
SG (3) | SG10201802926XA (fr) |
SI (2) | SI3456333T1 (fr) |
TN (1) | TN2015000249A1 (fr) |
UA (2) | UA117116C2 (fr) |
WO (1) | WO2014088785A1 (fr) |
ZA (2) | ZA201504124B (fr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1778711T (pt) | 2004-07-02 | 2017-10-19 | Geron Corp | Síntese de monómeros nucleosídeos 3'-amino protegidos |
ES2717777T3 (es) * | 2013-11-06 | 2019-06-25 | Mayo Found Medical Education & Res | Métodos y materiales para tratar neoplasias hematológicas |
SI3286203T1 (sl) * | 2015-04-23 | 2020-10-30 | Geron Corporation | Metode priprave polinukleotida, z uporabo sestavkov multivalentne kationske soli |
EP3318276A1 (fr) | 2016-11-04 | 2018-05-09 | Janssen Biotech, Inc. | Combinaisons d'un inhibiteur de la télomérase et d'un inhibiteur du bcl-2 destinées au traitement des cancers hématologiques |
TW201919705A (zh) * | 2017-07-28 | 2019-06-01 | 美商健生生物科技公司 | 治療骨髓增生不良症候群之方法 |
AU2019263064A1 (en) * | 2018-04-30 | 2020-12-03 | Kartos Therapeutics, Inc. | Methods of treating cancer |
WO2021091904A1 (fr) * | 2019-11-04 | 2021-05-14 | Geron Corporation | Utilisation d'un inhibiteur de janus kinase et d'un inhibiteur de télomérase pour le traitement de néoplasmes myéloprolifératifs |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5489508A (en) | 1992-05-13 | 1996-02-06 | University Of Texas System Board Of Regents | Therapy and diagnosis of conditions related to telomere length and/or telomerase activity |
US5958680A (en) | 1994-07-07 | 1999-09-28 | Geron Corporation | Mammalian telomerase |
US5583016A (en) | 1994-07-07 | 1996-12-10 | Geron Corporation | Mammalian telomerase |
US5863936A (en) | 1995-04-18 | 1999-01-26 | Geron Corporation | Telomerase inhibitors |
US5656638A (en) | 1995-04-18 | 1997-08-12 | Geron Corporation | Telomerase inhibitors |
US5760062A (en) | 1995-04-18 | 1998-06-02 | Geron Corporation | Telomerase inhibitors |
US5770613A (en) | 1995-09-29 | 1998-06-23 | Geron Corporation | Telomerase inhibitors |
US5767278A (en) | 1995-10-06 | 1998-06-16 | Geron Corporation | Telomerase inhibitors |
US6261836B1 (en) | 1996-10-01 | 2001-07-17 | Geron Corporation | Telomerase |
US6444650B1 (en) | 1996-10-01 | 2002-09-03 | Geron Corporation | Antisense compositions for detecting and inhibiting telomerase reverse transcriptase |
WO1998028442A1 (fr) | 1996-12-20 | 1998-07-02 | Geron Corporation | Procedes de detection et d'inhibition de la telomerase dans l'arn |
US6331399B1 (en) | 2000-05-16 | 2001-12-18 | Isis Pharmaceuticals, Inc. | Antisense inhibition of tert expression |
JP2007525414A (ja) * | 2003-01-31 | 2007-09-06 | ジェシー エル エス オウ | スラミン、ペントサン・ポリサルフェート、テロメラーゼアンチセンス、及びテロメラーゼ阻害剤を用いるための方法及び成分 |
CN1244592C (zh) * | 2003-07-11 | 2006-03-08 | 暨南大学 | 抑制白血病细胞端粒酶活性的反义核酸及其应用 |
EP3682903A1 (fr) | 2003-09-09 | 2020-07-22 | Geron Corporation | Oligonucléotides modifiés pour l'inhibition de la télomérase |
US20050282893A1 (en) * | 2004-01-30 | 2005-12-22 | Au Jessie L | Methods and compositions for using suramin, pentosan, polysulfate, telomerase antisense and telomerase inhibitors |
PT1778711T (pt) | 2004-07-02 | 2017-10-19 | Geron Corp | Síntese de monómeros nucleosídeos 3'-amino protegidos |
FR2877013A1 (fr) | 2004-10-27 | 2006-04-28 | Assist Publ Hopitaux De Paris | Indentification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez |
US20060166221A1 (en) | 2005-01-21 | 2006-07-27 | Bahou Wadie F | Methods of diagnosing essential thrombocythemia |
WO2006113426A2 (fr) * | 2005-04-15 | 2006-10-26 | Geron Corporation | Traitement de cancer par inhibition combinee des activites de la telomerase et de la tubuline |
WO2006113470A2 (fr) | 2005-04-15 | 2006-10-26 | Geron Corporation | Procede pour traiter un cancer grace a l'inhibition combinee d'activites de proteasome et de telomerase |
US20070224598A1 (en) | 2006-03-15 | 2007-09-27 | The Methodist Hospital Research Institute | System and method for detection of mutations in JAK2 polynucleotides |
US20080021013A1 (en) | 2006-07-21 | 2008-01-24 | Cephalon, Inc. | JAK inhibitors for treatment of myeloproliferative disorders |
HUE041448T2 (hu) | 2006-10-30 | 2019-05-28 | Geron Corp | Kombinált telomerázgátló és gemcitabin rák kezelésére |
CN101220044B (zh) * | 2008-01-21 | 2010-06-02 | 中国药科大学 | 端粒酶抑制剂及其制备方法和用途 |
-
2013
- 2013-11-15 UA UAA201505480A patent/UA117116C2/uk unknown
- 2013-11-15 SG SG10201802926XA patent/SG10201802926XA/en unknown
- 2013-11-15 KR KR1020217026717A patent/KR102662590B1/ko active IP Right Grant
- 2013-11-15 AP AP2015008504A patent/AP2015008504A0/xx unknown
- 2013-11-15 EP EP18196690.4A patent/EP3456333B8/fr active Active
- 2013-11-15 JP JP2015546492A patent/JP6433911B2/ja active Active
- 2013-11-15 SI SI201331716T patent/SI3456333T1/sl unknown
- 2013-11-15 CA CA2892907A patent/CA2892907C/fr active Active
- 2013-11-15 NZ NZ708920A patent/NZ708920A/en unknown
- 2013-11-15 AU AU2013356533A patent/AU2013356533B2/en active Active
- 2013-11-15 ES ES18196690T patent/ES2789176T3/es active Active
- 2013-11-15 KR KR1020237005641A patent/KR20230028590A/ko not_active Application Discontinuation
- 2013-11-15 BR BR112015013260-0A patent/BR112015013260A2/pt not_active Application Discontinuation
- 2013-11-15 ME MEP-2019-273A patent/ME03538B/fr unknown
- 2013-11-15 RS RS20200723A patent/RS60401B1/sr unknown
- 2013-11-15 KR KR1020157017240A patent/KR102294819B1/ko active IP Right Grant
- 2013-11-15 CN CN201380069553.6A patent/CN104936602B/zh active Active
- 2013-11-15 HU HUE13861008A patent/HUE045098T2/hu unknown
- 2013-11-15 FI FIEP19187756.2T patent/FI3646876T3/fi active
- 2013-11-15 MA MA45504A patent/MA45504B1/fr unknown
- 2013-11-15 SG SG10202103341SA patent/SG10202103341SA/en unknown
- 2013-11-15 PT PT181966904T patent/PT3456333T/pt unknown
- 2013-11-15 PT PT138610084T patent/PT2928477T/pt unknown
- 2013-11-15 PL PL13861008T patent/PL2928477T3/pl unknown
- 2013-11-15 EA EA201590878A patent/EA032973B1/ru unknown
- 2013-11-15 LT LTEP18196690.4T patent/LT3456333T/lt unknown
- 2013-11-15 WO PCT/US2013/070437 patent/WO2014088785A1/fr active Application Filing
- 2013-11-15 SI SI201331556T patent/SI2928477T1/sl unknown
- 2013-11-15 ES ES13861008T patent/ES2744790T3/es active Active
- 2013-11-15 EP EP19187756.2A patent/EP3646876B1/fr active Active
- 2013-11-15 MY MYPI2015001459A patent/MY180634A/en unknown
- 2013-11-15 SG SG11201504383TA patent/SG11201504383TA/en unknown
- 2013-11-15 DK DK19187756.2T patent/DK3646876T3/da active
- 2013-11-15 DK DK13861008.4T patent/DK2928477T3/da active
- 2013-11-15 UA UAA201800703A patent/UA126015C2/uk unknown
- 2013-11-15 LT LTEP19187756.2T patent/LT3646876T/lt unknown
- 2013-11-15 CA CA3188494A patent/CA3188494A1/fr active Pending
- 2013-11-15 HU HUE18196690A patent/HUE049858T2/hu unknown
- 2013-11-15 PL PL18196690T patent/PL3456333T3/pl unknown
- 2013-11-15 RS RSP20191271 patent/RS59363B1/sr unknown
- 2013-11-15 CN CN202010575187.3A patent/CN111617252A/zh active Pending
- 2013-11-15 LT LTEP13861008.4T patent/LT2928477T/lt unknown
- 2013-11-15 MX MX2015007169A patent/MX2015007169A/es active IP Right Grant
- 2013-11-15 MA MA38193A patent/MA38193B1/fr unknown
- 2013-11-15 DK DK18196690.4T patent/DK3456333T3/da active
- 2013-11-15 EP EP13861008.4A patent/EP2928477B1/fr active Active
-
2015
- 2015-06-04 CL CL2015001530A patent/CL2015001530A1/es unknown
- 2015-06-05 PH PH12015501282A patent/PH12015501282A1/en unknown
- 2015-06-05 TN TNP2015000249A patent/TN2015000249A1/fr unknown
- 2015-06-05 MX MX2022015437A patent/MX2022015437A/es unknown
- 2015-06-05 MX MX2020003276A patent/MX2020003276A/es unknown
- 2015-06-07 IL IL23926615A patent/IL239266B/en active IP Right Grant
- 2015-06-08 ZA ZA2015/04124A patent/ZA201504124B/en unknown
- 2015-11-27 HK HK15111700.1A patent/HK1210940A1/xx unknown
-
2016
- 2016-01-08 HK HK16100186.6A patent/HK1212226A1/xx unknown
-
2017
- 2017-08-24 CL CL2017002156A patent/CL2017002156A1/es unknown
- 2017-12-04 JP JP2017232485A patent/JP6998191B2/ja active Active
-
2018
- 2018-12-20 AU AU2018282364A patent/AU2018282364A1/en not_active Abandoned
-
2019
- 2019-10-02 HR HRP20191784TT patent/HRP20191784T1/hr unknown
- 2019-10-14 CY CY20191101076T patent/CY1122169T1/el unknown
- 2019-12-23 JP JP2019231517A patent/JP2020041001A/ja active Pending
-
2020
- 2020-06-23 CY CY20201100568T patent/CY1123206T1/el unknown
- 2020-06-24 HR HRP20200993TT patent/HRP20200993T1/hr unknown
- 2020-11-09 AU AU2020267142A patent/AU2020267142B2/en active Active
-
2021
- 2021-01-13 IL IL280144A patent/IL280144A/en unknown
- 2021-11-12 ZA ZA2021/08991A patent/ZA202108991B/en unknown
-
2022
- 2022-01-06 JP JP2022000951A patent/JP7288098B2/ja active Active
- 2022-10-12 JP JP2022163881A patent/JP2022179684A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA38193A1 (fr) | Utilisation d'inhibiteurs de télomérase pour le traitement de troubles myéloprolifératifs et de néoplasies myéloprolifératives | |
MA34248B1 (fr) | 5-fluoro-1h-pyrazolopyridines substituées et leur utilisation | |
MA35365B1 (fr) | Pyrimidines annelées substituées et leur utilisation | |
MA39211A1 (fr) | Composés tricycliques comme agents anti-cancers | |
MA35661B1 (fr) | Inhibiteurs de pak pour le traitement de troubles de prolifération cellulaire | |
CL2012003427A1 (es) | Compuestos derivados de 5-amino-3,6-dihidro-1h-pirazina-2-ona; y uso en el tratamiento de enfermedades tales como alzheimer, senilidad, demencia, entre otras. | |
EA201270803A1 (ru) | Тиоацетатные соединения, композиции на их основе и способы их применения | |
MA35844B1 (fr) | Pyrimidines et triazines annelées substituées et leur utilisation | |
WO2014039513A3 (fr) | Inhibition de la diacylglycérol kinase pour augmenter le transfert de lymphocyte t adoptif | |
CA2840307C (fr) | Cellules progenitrices d'une lignee mesodermique | |
WO2014153069A3 (fr) | Compositions et procédés de reprogrammation de lignées de cellules souches hématopoïétiques | |
TN2014000061A1 (en) | COMPOUNDS AND COMPOSITIONS AS c-KIT KINASE INHIBITORS | |
MA34818B1 (fr) | Anticorps anti-pcsk9 et procédés d'utilisation | |
MX2015002289A (es) | Anticuerpos humanos para gfr alfa 3 y métodos para su uso. | |
EA201490563A1 (ru) | Антисмысловые олигонуклеотиды для лечения врожденного амавроза лебера | |
MA38925B1 (fr) | Dérivés de phénylalanine substitués | |
MX2011012680A (es) | Ligandos peptoides para aislamiento y tratamiento de celulas-t autoinmune. | |
UA111520C2 (uk) | [1,2,4]триазолопіридини і їх застосування як інгібіторів фосфодіестерази | |
MA34291B1 (fr) | Compositions et méthodes de diagnostic et de traitement d'une tumeur | |
MA54889B1 (fr) | Utilisation d'inhibiteurs de télomérase pour le traitement de troubles myéloprolifératifs et de néoplasies myéloprolifératives | |
WO2012009640A3 (fr) | Appauvrissement en cellules b pour traiter des lésions du système nerveux central et procédés et utilisations connexes | |
BR112015024516A2 (pt) | métodos para identificar pacientes em risco de rejeição resistente ao bloqueio de coestimulação | |
Schroeder et al. | Non-specific low back pain. | |
EA201990799A1 (ru) | Использование ингибиторов теломеразы для лечения миелопролиферативных нарушений и миелопролиферативных неоплазм | |
Crutcher | PROVING GOD: THE QUESTION OF TRANSCENDENCE AND THE LIMITS OF RATIONALITY. |